相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction
Robert W. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
S. Nylander et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
David A. Morrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
Jing Ni et al.
CANCER DISCOVERY (2012)
Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel
N. S. Kirkby et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis
J. J. J. van Giezen et al.
THROMBOSIS RESEARCH (2009)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PI 3-kinase p110β:: a new target for antithrombotic therapy
SP Jackson et al.
NATURE MEDICINE (2005)
分享论文
